Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG-M108 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in CLDN18.2-positive first-line advanced pancreatic cancer
CTR20260995Phase 3Active
- Sponsor
- Mingji Biopharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of M108 in pancreatic adenocarcinoma (PDAC), sponsored by Mingji Biopharmaceutical. Started Mar 2026; status: active.
02
Drugs
M108
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20260995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260995.